Reported Earlier, Immunic Presents Data From Phase 1b Clinical Trial Of IMU-856 In Celiac Disease At The United European Gastroenterology Week 2023
Portfolio Pulse from Benzinga Newsdesk
Immunic has presented data from its Phase 1b clinical trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023.
October 16, 2023 | 6:49 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immunic's presentation of Phase 1b clinical trial data for IMU-856 could potentially impact its stock price.
The presentation of positive clinical trial data often leads to increased investor confidence, which can drive up the stock price. However, the exact impact will depend on the specifics of the data presented.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100